XML 94 R83.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Segment, Geographic and Other Revenue Information - Revenues by Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jul. 02, 2023
Jun. 30, 2024
Jul. 02, 2023
Revenue from External Customer [Line Items]        
Revenues: $ 13,283 $ 13,007 $ 28,162 $ 31,492
Alliance revenues [1] 2,067 1,967 4,240 4,028
Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 12,991 12,690 27,595 30,863
Biopharma [Member] | U.S. Commercial Division [Member]        
Revenue from External Customer [Line Items]        
Revenues: 4,911 4,200 11,764 10,815
Biopharma [Member] | Oncology Division [Member]        
Revenue from External Customer [Line Items]        
Revenues: 2,918 2,167 5,490 4,150
Biopharma [Member] | International Commercial Division [Member]        
Revenue from External Customer [Line Items]        
Revenues: 5,163 6,323 10,341 15,898
Pfizer CentreOne [Member]        
Revenue from External Customer [Line Items]        
Revenues: [2] 278 307 535 615
Pfizer Ignite [Member]        
Revenue from External Customer [Line Items]        
Revenues: 15 10 32 14
Total Alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Alliance revenues 2,067 1,967 4,240 4,028
Royalty revenues        
Revenue from External Customer [Line Items]        
Royalty revenue [1] 345 273 608 477
Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 4,952 5,884 12,163 17,444
Primary Care [Member] | Eliquis [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [3] 1,877 1,762 3,917 3,636
Primary Care [Member] | Prevnar Family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,359 1,431 3,050 3,033
Primary Care [Member] | Paxlovid [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [4] 251 143 2,286 4,212
Primary Care [Member] | Comirnaty [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 195 1,488 548 4,552
Primary Care [Member] | Nurtec ODT/Vydura [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 356 247 533 414
Primary Care [Member] | Abrysvo [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 56 0 201 0
Primary Care [Member] | Premarin family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 108 95 193 207
Primary Care [Member] | FSME-IMMUN/TicoVac [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 100 101 165 146
Primary Care [Member] | All other Primary Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 651 616 1,269 1,244
Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 4,083 3,656 7,926 7,272
Specialty Care [Member] | Vyndaqel family [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,323 782 2,460 1,468
Specialty Care [Member] | Xeljanz [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 303 469 497 706
Specialty Care [Member] | Enbrel (Outside the U.S. and Canada) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 179 219 338 419
Specialty Care [Member] | Sulperazon [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 144 177 311 497
Specialty Care [Member] | Zavicefta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 150 132 275 248
Specialty Care [Member] | Zithromax [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 74 44 274 194
Specialty Care [Member] | Inflectra [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 97 74 255 252
Specialty Care [Member] | Genotropin [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 119 74 239 222
Specialty Care [Member] | BeneFIX [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 103 106 206 215
Specialty Care [Member] | Octagam [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 104 66 179 111
Specialty Care [Member] | Oxbryta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 92 77 176 148
Specialty Care [Member] | Cibinqo [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 47 38 89 54
Specialty Care [Member] | All other Hospital [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [5] 1,114 1,213 2,188 2,365
Specialty Care [Member] | All other Specialty Care [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 234 185 440 373
Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 3,956 3,149 7,505 6,146
Oncology [Member] | Ibrance [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 1,130 1,247 2,184 2,391
Oncology [Member] | Xtandi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [6] 495 423 913 763
Oncology [Member] | Padcev [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 394 0 735 0
Oncology [Member] | Oncology Biosimilars [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [7] 279 363 543 775
Oncology [Member] | Adcetris [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 279 0 536 0
Oncology [Member] | Inlyta [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 252 262 489 521
Oncology [Member] | Lorbrena [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 169 121 332 234
Oncology [Member] | Bosulif [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 167 154 313 304
Oncology [Member] | Braftovi/Mektovi [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: [8] 148 113 264 215
Oncology [Member] | Tukysa [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 121 0 227 0
Oncology [Member] | Tivdak [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 33 0 60 0
Oncology [Member] | Talzenna [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: 32 12 55 22
Oncology [Member] | All other Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues: $ 457 $ 455 $ 853 $ 923
[1] See Note 1A.
[2] PC1 includes revenues from our contract manufacturing and our active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with legacy Pfizer businesses/partnerships.
[3] Primarily reflects Alliance revenues and product revenues.
[4] The first six months of 2024 includes a $771 million favorable final adjustment recorded in the first quarter of 2024 to the estimated non-cash revenue reversal of $3.5 billion recorded in the fourth quarter of 2023, reflecting 5.1 million EUA-labeled treatment courses returned by the U.S. government through February 29, 2024 versus the estimated 6.5 million treatment courses that were expected to be returned as of December 31, 2023.
[5] Includes, among other Hospital products, amounts previously presented as All other Anti-infectives and Ig Portfolio.
[6] Primarily reflects Alliance revenues and royalty revenues.
[7] Biosimilars are highly similar versions of approved and authorized biological medicines. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym.
[8] Erbitux is a registered trademark of ImClone LLC.